HCM
$14.30
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
Recent News
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ...
Despite challenges, HUTCHMED (China) Ltd (HCM) reports robust sales growth and outlines ambitious oncology revenue targets for 2026.
Sector Update: Health Care Stocks Decline Premarket Monday
Health care stocks were declining premarket Monday, with the State Street Health Care Select Sector
Hutchmed price target lowered to $21 from $22 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $21 from $22 and keeps a Buy rating on the shares. The firm says Hutchmed’s FY25 print “offered some positive steps forward after a weaker 1H25.” Directional commentary about fruquintinib indication expansion in 2026 and increasing the number of Fruzaqla markets bolsters the firm’s confidence that Hutchmed can meet their 2026 guidance for Oncology/Immunology, the analyst tells investors.Claim 70% Off TipRanks Premiu
HUTCHMED H2 Earnings Call Highlights
HUTCHMED (NASDAQ:HCM) management used its 2025 annual results call to highlight growth in global sales for FRUZAQLA, a rebound in China market performance in the second half, and increasing investment behind its ATTC (antibody-targeted therapy conjugate) platform as it advances multiple assets into
Paycom Software, Inc. (PAYC): A Bull Case Theory
We came across a bullish thesis on Paycom Software, Inc. on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on PAYC. Paycom Software, Inc.’s share was trading at $134.75 as of January 30th. PAYC’s trailing and forward P/E were 16.69 and 13.16 respectively according to Yahoo Finance. Paycom Software, Inc. provides a […]